Healthcare

Meet your Healthcare Research team

UDG Healthcare plc

30% relative valuation gap to US peers provides opportunity

UDG delivered an excellent set of H1 20 results and, although backward looking, these should prove indicative of the strength of its operating model once current disruptions ease....

Amryt Pharma

New Amryt, strong off the blocks

Amryt’s results this morning provide us with more clarity on how it is performing post the Aegerion acquisition (late Q3 2019). The numbers are impressive; strong revenue growth,...

Amryt Pharma

Timelines firmed up for AP101 trial

Amryt has closed enrolment in its AP101 Phase III trial for epidermolysis bullosa (EB). This decision was made in light of COVID-19 impacts on patient recruitment and given that the trial...

UDG Healthcare plc

Trading and COVID-19 update

Who knows where FY 2020 EPS for UDG Healthcare (UDG) will land; flat year-on-year (yoy)? -10% yoy? In many respects, this misses the point. We know that UDG’s balance sheet is in...

Uniphar

FY 2019: delivering to plan; valuation highly attractive

Uniphar continues to build a track record post IPO of delivering on both strategy and numbers. This morning’s trading update suggests that it is on track to meet our 2019 forecasts....

Malin Corporation

3D4 Medical sold at 10% premium

Malin has announced the sale of 3D4 Medical for an estimated €45m/$50m, of which Malin will net cash proceeds of €17m. This sale is evidence of Malin executing on its strategy to realise...

UDG Healthcare plc

In excellent health for 2020

UDG has reported a strong set of FY 2019 results at the top end of EPS guidance, with both Ashfield Communications & Advisory (C&A) and Sharp (c.80% of profits) delivering ahead of...

Amryt Pharma

Aegerion deal unlocks global opportunity

The Aegerion deal is clearly transformational; however, of greater interest, is that value accretion for shareholders is just beginning. The enlarged group has a global platform to...

UDG Healthcare plc

Delivering to plan; building a leading advisory business

UDG Healthcare has committed c.$250m in the last three years in delivering on its strategy to build an advisory business within Ashfield. This now accounts for over 20% of group profit...

Malin Corporation

H1 2019 results: value/price disconnect compelling

The modest 5% reduction in Malin’s IPEV stands in stark contrast to its 52% share price decline year-to-date. The latter is largely driven by overhang concerns due to Woodford IM’s...